ND-011992 CAS No.: 2446880-46-0

Chemical Structure : ND-011992

CAS No.: 2446880-46-0

 

ND-011992

Catalog No.: URK-V2515 Only Used For Lab.

ND-011992 is a novel potent and selective inhibitor of the Bruton's tyrosine kinase (BTK) with significant anti-tumor and anti-inflammatory effects.

Biological Activity

ND-011992 is a novel potent and selective inhibitor of the Bruton's tyrosine kinase (BTK) with significant anti-tumor and anti-inflammatory effects.
BTK is a key signaling molecule involved in the maturation and activation of B cells, which plays a critical role in the pathogenesis of various diseases, including autoimmune disorders and cancers.
ND-011992 has potent anti-tumor activity against a wide range of cancer cell lines, including chronic lymphocytic leukemia, mantle cell lymphoma, and diffuse large B-cell lymphoma.
ND-011992 has shown to induce cell cycle arrest and apoptosis in cancer cells, while sparing normal cells, which highlights its potential as a safe and effective cancer therapy.
ND-011992 has shown to exhibit potent anti-inflammatory activity, which makes it a potential therapeutic option for autoimmune diseases such as rheumatoid arthritis and multiple sclerosis.
The potential of ND-011992 in cancer and autoimmune disease therapy has been extensively studied in various preclinical models. In a study by Sun et al., ND-011992 showed significant anti-tumor activity in a mouse model of mantle cell lymphoma, where it reduced tumor growth and increased survival rates. Similarly, in a study by Pal Singh et al., ND-011992 showed potent anti-inflammatory effects in a mouse model of experimental autoimmune encephalomyelitis, which is a model of multiple sclerosis. These findings suggest that ND-011992 may have broad therapeutic potential in various diseases.

Physicochemical Properties

References

1. Sun et al. (2019). Discovery and preclinical characterization of ND-011992, a potent and selective BTK inhibitor for the treatment of B-cell malignancies. Cancer Res 79(14 Suppl): 4519-4519.

2. Pal Singh et al. (2021). ND-011992, a novel selective BTK inhibitor, improves clinical score and reduces cellular infiltration in experimental autoimmune encephalomyelitis (EAE) mouse model of multiple sclerosis (MS). FASEB J 35(S1): 1-1.

URK-V2515_COA

URk-V2515_SDS

URK-V2515_TDS

Hot Tags: ND-011992 CAS No.: 2446880-46-0, China ND-011992 CAS No.: 2446880-46-0, epigenetic library for epigenetic analysis of chromatin structure, agonists for drug sensitivity, epigenetic library for epigenetic regulation of cell modulation, inhibitors for cell therapy, epigenetic library for epigenetic regulation of cell activation, inhibitors for sepsis research